K. H. Crawford, A. Dingens, R. Eguia, C. Wolf, N. Wilcox, J. Logue, K. Shuey, A. Casto, B. Fiala, S. Wrenn, D. Pettie, N. King, A. Greninger, H. Chu, J. Bloom
The Journal of infectious diseases, 2020
Most individuals infected with SARS-CoV-2 develop neutralizing antibodies that target the viral spike protein. Here we quantify how levels of these antibodies change in the months following SARS-CoV-2 infection by examining longitudinal samples collected between ~30 and 152 days post symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about four-fold from one to four months post symptom onset. This decline in neutralizing antibody titers was accompanied by a decline in total antibodies capable of binding the viral spike or its receptor-binding domain. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B-cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.
Cited by 27 publications.
Field of study: Medicine